Papadopoulos, K.P., Owonikoko, T.K., Johnson, M.L., Brana, I., Gil-Martin, M., Perez, R.P., Moreno, V., Salama, A.K., Calvo, E., Yee, N.S., Safran, H., Gonzalez-Martin, A., Aljumaily, R., Mahadevan, D., Mohan, K.K., Li, J., Stankevich, E., Lowy, I., Fury, M.G. and Homsi, J. 2018. Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study. SKIN The Journal of Cutaneous Medicine. 2, S1 (Feb. 2018), S45. DOI:https://doi.org/10.25251/skin.2.supp.45.